ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Has Received An Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Central Drugs Standard Control Organisation, Directorate General Of Health Services, Government Of India For Dapagliflozin (Forxiga(r)) Tablets Of 10 Mg - Additional/ Extended Indication
Please find the enclosed letter of the Company in relation to the captioned subject for your reference. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2022 for your information and records. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for Loss of Share Certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed extract of the Newspaper Publication as on November 12, 2022 for the Financial Results for your reference. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated November 8, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Of Re-Appointment Of Mr. Rajesh Marwaha As Whole-Time Director Of The Company Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the re-appointment of Mr. Rajesh Marwaha (DIN: 01458768), Chief Financial Officer and Director of the Company as Whole-time Director for a further period of three (3) years with effect from December 2, 2022 subject to the approval of the Members of the Company through Postal Ballot. Brief details of Mr. Rajesh Marwaha are enclosed below as 'Annexure- A'. Kindly take the above on your records. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Friday, November 11, 2022 Pursuant To Regulations 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find the enclosed file as per the captioned subject for your reference. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, November 11, 2022 Pursuant To Regulations 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find the enclosed file relating to the captioned subject for your reference. The Meeting commenced at 1:30 P.M. and concluded at 3:30 P.M.(IST). ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant.